Efficacy of chemotherapy according to status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse.
Fiche publication
Date publication
janvier 2023
Journal
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric
Tous les auteurs :
Brouillard-Saby F, Saint-Martin C, Ray-Coquard I, Gladieff L, Pomel C, Colombo PE, Classe JM, Chevrier M, Joly F, De la Motte Rouge T, Floquet A, Sabatier R, Barranger E, Costaz H, Leblanc E, Marchal F, Pautier P, Bosquet L, Rodrigues M
Lien Pubmed
Résumé
Chemotherapy for high-grade serous ovarian cancers in platinum-sensitive relapse includes carboplatin/paclitaxel, carboplatin/gemcitabine, and carboplatin/pegylated liposomal doxorubicin. According to data, mutated patients are sensitive to replicative stress agents but status is not yet used for the choice of chemotherapy at relapse. Our aim was to assess these doublets according to status in first platinum-sensitive relapse.
Mots clés
BRCA1 Protein, Cystadenocarcinoma, Serous, Gynecology, Neoplasm Recurrence, Local, Ovarian Cancer
Référence
Int J Gynecol Cancer. 2023 01 11;: